Please login to the form below
Teva and Novartis settle patent lawsuit
Teva Pharmaceuticals will settle patent litigation with Novartis involving Teva's US generic version of antiviral medication Famvir
Teva Pharmaceuticals, US, has signed an agreement with Novartis to settle patent litigation involving Teva's US generic version of the Novartis-developed antiviral medication Famvir (famciclovir).
The settlement includes all claims for patent infringement and damages.
Under the terms of the agreement, Israel-based Teva will make an undisclosed one-time payment to Novartis plus ongoing royalties on US sales of its product, which is used to treat herpes and shingles.
Teva is among the top 15 global pharmaceutical companies and is a leading generic pharmaceutical company. Teva launched the generic version of Famvir in September 2007.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- New data backs remdesivir for COVID-19, but rings hydroxychloroquine alarm bell
- How will the events and exhibitions industry change post-Coronavirus?
- UK government and GSK/Sanofi sign COVID-19 vaccine supply deal
- COVID-19 round-up: WHO pulls hydroxychloroquine study, UK restricts dexamethasone exports, and more
- The blurred lines between sepsis and COVID-19
- Roche’s Tecentriq combo scores FDA approval for melanoma
- Gut instincts lead Takeda to GI pipeline success
- Live Webinar: Using Health IT to Improve the Healthcare System
- J&J’s COVID-19 vaccine generates positive pre-clinical results
- Gilead’s top-line slips 10% as demand for HIV/hepatitis C drugs drops
- NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer
- Roche’s Tecentriq combo scores FDA approval for melanoma
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...
Latest intelligence
- Gut instincts lead Takeda to GI pipeline success
- Takeda’s Asit Parikh talks about a game changer for IBD patients and the company’s long-term strategy for gene and cell therapy...
- Covid-19 drives change in long-term conditions management
- Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore how patients are being empowered to manage their conditions at home...
- The importance of health literacy in patient recruitment materials
- Have you ever read something that instantly made you want to read on? Or have you begun to read something, and eventually given up because it didn’t resonate with you?...
Quick links
Infographics
